Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma-Reference-Cited by-同舟云学术

Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma

Published:2022-06-16 Issue:2 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Sun Stella¹,Kiang Karrie¹,Leung Gilberto¹

Affiliation:

1. Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR 999077, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference22 articles.

1. Multiple high-grade gliomas: Epidemiology, management, and outcome. A systematic review and meta-analysis;Di Carlo;Neurosurg Rev,2019

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

4. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways;Sun;Neuro Oncol,2013

5. The endoplasmic reticulum and the unfolded protein response;Malhotra;Semin Cell Dev Biol,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance;Cancer Science;2023-12-15

2. COL15A1 interacts with P4HB to regulate the growth and malignancy of HepG2.2.15 cells;Biochemical and Biophysical Research Communications;2023-11

3. A meta-analysis and bioinformatics analysis of P4HB expression levels in the prognosis of cancer patients;Pathology - Research and Practice;2023-05

4. Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma;British Journal of Cancer;2023-03-17

5. Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel;aging and disease;2023